Title |
Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
|
---|---|
Published in |
Diabetes Therapy, October 2014
|
DOI | 10.1007/s13300-014-0086-7 |
Pubmed ID | |
Authors |
Kohei Kaku, Hiroshi Maegawa, Yukio Tanizawa, Arihiro Kiyosue, Yumiko Ide, Takuto Tokudome, Yuji Hoshino, Jisin Yang, Anna Maria Langkilde |
Abstract |
Dapagliflozin is a selective sodium glucose co-transporter 2 inhibitor that improves glycemic control and reduces body weight and systolic blood pressure in patients with type 2 diabetes mellitus (T2DM). Dapagliflozin is effective and well tolerated over 12-24 weeks in Japanese patients with T2DM. In this study, the safety and efficacy of dapagliflozin administered as monotherapy and combination therapy were assessed over 52 weeks in Japanese patients with T2DM. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 56 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 10 | 18% |
Student > Master | 7 | 13% |
Researcher | 7 | 13% |
Student > Doctoral Student | 3 | 5% |
Other | 3 | 5% |
Other | 7 | 13% |
Unknown | 19 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 36% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 18% |
Nursing and Health Professions | 3 | 5% |
Engineering | 2 | 4% |
Unspecified | 1 | 2% |
Other | 1 | 2% |
Unknown | 19 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 November 2021.
All research outputs
#6,137,513
of 22,768,097 outputs
Outputs from Diabetes Therapy
#220
of 1,013 outputs
Outputs of similar age
#67,203
of 260,971 outputs
Outputs of similar age from Diabetes Therapy
#3
of 10 outputs
Altmetric has tracked 22,768,097 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,013 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,971 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.